FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
SCANGOS GEORGE A								2		ı			X Direc	tor		10% Ow	ner		
(Last)	(F	irst)	(Middle)		Date of Earliest Transaction (Month/Day/Year)								X Officion below	er (give title v)		Other (s below)	pecify		
BIOGEN IDEC INC.						02/10/2011								Chief Executive Officer					
133 BOS	STON POST	ΓROAD		L															
(Street)					. If Ame	endment, I	Date o	f Original Fi	iled (N	Month/Da		6. Individual or Joint/Group Filing (Check Applicable Line)							
WESTON MA 02493												X Form	filed by On	filed by One Reporting Person					
													Form Pers		re thar	One Repor	ting		
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-	Derivati	ve Se	curities	s Ac	quired, D	ispo	osed o	f, or Be	neficia	lly Owne	d					
Date				2. Transactio Date Month/Day/		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefi Owned	ies cially Following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									, ,	Amount	(A) oi (D)	Price	Report Transa (Instr.	ed ction(s) 3 and 4)			(Instr. 4)		
		-	Table II - D (e					uired, Dis					y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration I (Month/Day	Date	of Securities		ies g Security	Derivativ Security		e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	· v	(A)	(D)	Date Exercisable		piration te	Title	Amoun or Numbe of Shares							
Restricted Stock Unit	\$0 ⁽¹⁾	02/10/2011		A		75,332		(2)	02/	10/2015	Common Stock	75,33	2 \$0	75,33	2	D			

Explanation of Responses:

- 1. There is no conversion or exercise price for this stock unit.
- 2. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

Aras Lapinskas, Attorney in Fact for George A. Scangos

02/11/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.